ESR1 and breast carcinoma: Clinical trials have shown that the use of AIs increases disease-free survival and decreases the occurrence of contralateral breast cancer as compared with the use of selective estrogen receptor modulators, such as tamoxifen (Howell et al., 2005; Ferretti et al., 2006; Eisen et al., 2008; Forbes et al., 2008).